ReviewCancer medicine2022

Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.

Marcel SamboPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.